Dr. Maxwell Sauder is a dermatologist certified in Canada and the United States. He is the founder of Avenue Dermatology Group and founder and Research Director of Avenue Research Group in Toronto. He also serves as an Assistant Professor and Cutaneous Oncology Fellowship Director at the University of Toronto and an onco-dermatologist at Princess Margaret Cancer Centre.
Dr. Sauder earned his medical degree at McMaster University and completed his dermatology residency at the University of Ottawa. He pursued fellowship training in Cutaneous Oncology and Skin Toxicity at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, where he subsequently served as an Instructor in Dermatology.
His clinical and research interests include skin cancer, dermatologic toxicities of cancer therapies, and inflammatory skin disease. He has served as principal investigator on numerous clinical trials and authored more than 70 peer-reviewed publications, including articles in The New England Journal of Medicine, The Lancet, and JAMA Dermatology.
Dr. Sauder is an Ontario Regional Director of the Canadian Dermatology Association and a Councilor of the International Psoriasis Council. His work integrates clinical care, research, and medical education to advance dermatologic practice.
Speaking at Dermatology Update — Fall 2026
2 sessions
Friday, November 1317:10 – 17:4030 minOpen Pres.Speaker
Photodynamic therapy (PDT) remains an important treatment option for actinic keratosis (AK), offering a field-directed approach that can address both clinical and subclinical disease. In this expert panel discussion, leading Canadian dermatologists will review the evolving role and benefits of PDT in AK management. Attendees will gain an early look at key recommendations from the newly published Canadian PDT consensus paper developed by national experts to support best practices in clinical care and explore emerging evidence and unmet needs in post-PDT patient care.
Learning objectives
Review the role of photodynamic therapy (PDT) and its benefits in the management of actinic keratosis (AK), highlighting patient selection considerations, and real-world practice experience
Discuss key recommendations from the new Canadian PDT consensus paper, including best practices aimed at optimizing treatment outcomes and standardizing PDT use across clinical settings
Explore emerging evidence and unmet needs in post-PDT patient care
Dr. Charles Lynde
